Methypatch advisory committee review
Shire/Noven's methylphenidate patch, Methypatch, for attention deficit/hyperactivity disorder in children ages six to 12 will be reviewed by FDA's Psychopharmacologic Drugs Advisory Committee Dec. 2. Noven received a "not approvable" letter for its original application in April 2003 based on concerns over dosing, duration of wear and incidence of side effects. In June, the advisory committee recommended against adding warnings regarding psychiatric events to methylphenidate product labeling based on data that showed no new signal (1"The Pink Sheet" July 4, 2005, p. 3). The meeting will be held at the Hilton in Gaithersburg, Md...
You may also be interested in...
FDA should consider posting concerns about psychiatric and cardiovascular adverse events with Johnson & Johnson's Concerta and other methylphenidate products on the agency's upcoming "Drug Watch" website, members of FDA's Pediatric Advisory Committee said
The EU has just become the world’s biggest buyer of COVID-19 vaccines – and wants to make that purchasing power count in 2021 and beyond.
Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.